Cargando…

Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study

INTRODUCTION: Identifying polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) gene is gaining importance to be able to predict fluoropyrimidine-associated toxicity. The aim of this project was to describe the frequency of the DPYD variants DPYD*2A (rs3918290); c.1679T>G (rs55886062); c.28...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miarons, Marta, Manzaneque Gordón, Alba, Riera, Pau, Gutiérrez Nicolás, Fernando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166167/ https://www.ncbi.nlm.nih.gov/pubmed/37014829 http://dx.doi.org/10.1093/oncolo/oyad077

Ejemplares similares

Frequency of the DPYD * 2A allele in the Czech population
por: Koudová, Monika, et al.
Publicado: (2014)

A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening
por: Tong, Chi C., et al.
Publicado: (2018)

Revisiting the Clinical Importance of DPYD*9A (c.85T>C) Variant of Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients Treated with Fluoropyrimidine-Based Chemotherapy
por: Patel, Girijesh Kumar, et al.
Publicado: (2018)

Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity
por: Ockeloen, Charlotte W, et al.
Publicado: (2021)

Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients
por: Stavraka, Chara, et al.
Publicado: (2019)

Poor association between dihydropyrimidine dehydrogenase ( DPYD ) genotype and fluoropyrimidine‐induced toxicity in an Asian population
por: Kanai, Masashi, et al.
Publicado: (2022)

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients
por: Del Re, Marzia, et al.
Publicado: (2019)

Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants
por: Lunenburg, Carin A. T. C., et al.
Publicado: (2018)

Mutations at codon 974 of the DPYD gene are a rare event.
por: Ridge, S. A., et al.
Publicado: (1997)

Mutations at codon 974 of the DPYD gene are a rare event.
por: Diasio, R. B., et al.
Publicado: (1997)

DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report
por: Wigle, Theodore J., et al.
Publicado: (2019)

Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature
por: White, Cassandra, et al.
Publicado: (2021)

Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk
por: De Mattia, Elena, et al.
Publicado: (2022)

DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients
por: Amirfallah, Arsalan, et al.
Publicado: (2018)

New advances in DPYD genotype and risk of severe toxicity under capecitabine
por: Etienne-Grimaldi, Marie-Christine, et al.
Publicado: (2017)

Implementation and clinical benefit of DPYD genotyping in a Danish cancer population
por: Paulsen, N.H., et al.
Publicado: (2023)

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
por: Loganayagam, A, et al.
Publicado: (2013)

A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant
por: De Falco, Vincenzo, et al.
Publicado: (2019)

Influence of DPYD*9A, DPYD*6 and GSTP1 ile105val Genetic Polymorphisms on Capecitabine and Oxaliplatin (CAPOX) Associated Toxicities in Colorectal Cancer (CRC) Patients
por: K, Ashok Varma, et al.
Publicado: (2019)

Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic DPYD structural variant
por: Majounie, Elisa, et al.
Publicado: (2020)

Near Miss or Standard of Care? DPYD Screening for Cancer Patients Receiving Fluorouracil
por: Winquist, Lauren E., et al.
Publicado: (2020)

Concordance of Blood-Based and Normal Tissue-Based Dihydropyrimidine Dehydrogenase (DPYD) Genotyping
por: Morelli, Cristina, et al.
Publicado: (2022)

Importance of Rare DPYD Genetic Polymorphisms for 5-Fluorouracil Therapy in the Japanese Population
por: Hishinuma, Eiji, et al.
Publicado: (2022)

Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?
por: Maslarinou, Anthi, et al.
Publicado: (2023)

Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene
por: Maring, J G, et al.
Publicado: (2002)

A DPYD variant (Y186C) in individuals of African ancestry associated with reduced DPD enzyme activity
por: Offer, Steven M., et al.
Publicado: (2013)

Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
por: Zhang, Ting, et al.
Publicado: (2023)

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines
por: Lunenburg, Carin A. T. C., et al.
Publicado: (2019)

Potential Impact of DPYD Variation on Fluoropyrimidine Drug Response in sub-Saharan African Populations
por: da Rocha, Jorge E. B., et al.
Publicado: (2021)

DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation
por: Wigle, Theodore J., et al.
Publicado: (2023)

Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene
por: García-González, Xandra, et al.
Publicado: (2018)

97856 Implementation of DPYD and UGT1A1 pharmacogenetic testing to guide chemotherapy dosing
por: Varughese, Lisa A., et al.
Publicado: (2021)

DPYD, down-regulated by the potentially chemopreventive agent luteolin, interacts with STAT3 in pancreatic cancer
por: Kato, Hiroyuki, et al.
Publicado: (2021)

Genetic Variations of the DPYD Gene and Its Relationship with Ancestry Proportions in Different Ecuadorian Trihybrid Populations
por: Farinango, Camila, et al.
Publicado: (2022)

DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview
por: Paulsen, Niels Herluf, et al.
Publicado: (2022)

Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
por: Wu, Angela, et al.
Publicado: (2023)

An Evaluation of the Diagnostic Accuracy of a Panel of Variants in DPYD and a Single Variant in ENOSF1 for Predicting Common Capecitabine Related Toxicities
por: Palles, Claire, et al.
Publicado: (2021)

Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice
por: Saif, Muhammad Wasif, et al.
Publicado: (2020)

Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy
por: Amstutz, Ursula, et al.
Publicado: (2008)

Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis
por: Li, Qiang, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_cn23qi216ras1qvqfgg4nqm4fj